These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24299497)

  • 21. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension.
    Oertel W; Poewe W; Wolters E; De Deyn PP; Emre M; Kirsch C; Hsu C; Tekin S; Lane R
    Drug Saf; 2008; 31(1):79-94. PubMed ID: 18095748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exercise therapy for prevention of falls in people with Parkinson's disease: a protocol for a randomised controlled trial and economic evaluation.
    Canning CG; Sherrington C; Lord SR; Fung VS; Close JC; Latt MD; Howard K; Allen NE; O'Rourke SD; Murray SM
    BMC Neurol; 2009 Jan; 9():4. PubMed ID: 19161631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
    Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
    Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicentre, randomised controlled trial of PDSAFE, a physiotherapist-delivered fall prevention programme for people with Parkinson's.
    Chivers Seymour K; Pickering R; Rochester L; Roberts HC; Ballinger C; Hulbert S; Kunkel D; Marian IR; Fitton C; McIntosh E; Goodwin VA; Nieuwboer A; Lamb SE; Ashburn A
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):774-782. PubMed ID: 30944149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.
    Mäurer M; Ortler S; Baier M; Meergans M; Scherer P; Hofmann W; Tracik F
    Mult Scler; 2013 Apr; 19(5):631-8. PubMed ID: 23069874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine and Parkinson dementia complex.
    Moretti R; Torre P; Vilotti C; Antonello RM; Pizzolato G
    Expert Opin Pharmacother; 2007 Apr; 8(6):817-29. PubMed ID: 17425477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease.
    Di Giacopo R; Fasano A; Quaranta D; Della Marca G; Bove F; Bentivoglio AR
    Mov Disord; 2012 Apr; 27(4):559-61. PubMed ID: 22290743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease.
    Mancini M; Chung K; Zajack A; Martini DN; Ramsey K; Lapidus J; Horak FB; Nutt JG
    Parkinsonism Relat Disord; 2019 Dec; 69():40-47. PubMed ID: 31675664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.
    Koshy Cherian A; Kucinski A; Wu R; de Jong IEM; Sarter M
    Psychopharmacology (Berl); 2019 Jun; 236(6):1701-1715. PubMed ID: 30607479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naïve cohort.
    Lord S; Galna B; Yarnall AJ; Coleman S; Burn D; Rochester L
    Mov Disord; 2016 Dec; 31(12):1829-1836. PubMed ID: 27621153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial.
    Nieuwboer A; Kwakkel G; Rochester L; Jones D; van Wegen E; Willems AM; Chavret F; Hetherington V; Baker K; Lim I
    J Neurol Neurosurg Psychiatry; 2007 Feb; 78(2):134-40. PubMed ID: 17229744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive rehabilitation for Parkinson’s disease dementia: a study protocol for a pilot randomised controlled trial.
    Hindle JV; Watermeyer TJ; Roberts J; Martyr A; Lloyd-Williams H; Brand A; Gutting P; Hoare Z; Edwards RT; Clare L
    Trials; 2016 Mar; 17():152. PubMed ID: 27000036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.
    Schrag A; Carroll C; Duncan G; Molloy S; Grover L; Hunter R; Brown R; Freemantle N; Whipps J; Serfaty MA; Lewis G
    BMC Neurol; 2022 Dec; 22(1):474. PubMed ID: 36510237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.